INTRODUCTION
Obesity and the associated metabolic syndrome represent a major public health issue 1 and at present many patients remain refractory to weight loss by diet and exercise and existing pharmacological interventions. The obese transition leads to a deviation away from the main function of adipose tissue, that of effective and appropriately controlled fat storage and release, and adipose tissue dysfunction in obesity predisposes to the metabolic consequences of obesity, such as insulin resistance, diabetes and cardiovascular disease. A greater understanding of the molecular mechanisms underlying obesity and adipose tissue dysfunction will be required if we are to identify novel therapeutic targets.
MicroRNAs (miRNAs) are a novel group of small (approximately 22 nucleotide) non-coding RNAs that have emerged as important regulators of mRNA expression. MiRNAs are predicted to act on multiple targets 2 and quantitatively alter the expression of their target genes and proteins. MiRNAs therefore represent promising targets for modulating the complex pathways and as potential regulators of adipose tissue form and function, and the transcriptional programs that respond to 'stress' in adipose tissue in obesity. Since their discovery miRNAs have attracted considerable interest and the volume of research into them is growing exponentially. This review will examine advances in our understanding of miRNA's role in adipose tissue, discuss the dominant miRNA research techniques available and consider how miRNAs might be utilised therapeutically.
MiRNA STRUCTURE, SYNTHESIS AND ACTION
MiRNAs are found in all multicellular organisms from plants to humans and in many instances are highly conserved through evolution and therefore likely to be important for normal cellular function. Indeed, completely disrupting miRNA processing is lethal. 3 MiRNA biogenesis has been well reviewed elsewhere. 4, 5 Briefly, a primary miRNA, which may be several thousands of bases long, is cleaved by a protein complex containing the enzyme Drosha to give a precursor miRNA of around 70 nucleotides in a stem-loop structure. 6 This is then transported out of the nucleus into the cytoplasm and further processed by the enzyme Dicer to give a short double-stranded miRNA complex, which contains the mature miRNA strand and a passenger strand (miRNA*), which is normally degraded. The mature miRNA is incorporated with the Argonaute subfamily of proteins into the RNA-induced silencing complex. The miRNA then guides the RNA-induced silencing complex to a target mRNA, often by virtue of complementarity between the miRNA seed sequence and the 3 0 untranslated region of the target mRNA, although functional miRNA targeting can occur in other areas of the mRNA. 7, 8 Base pairing between the miRNA and its target is often imperfect causing repression of translation to protein, although highly complementary pairing may cause cleavage of the target mRNA. Translational activation by miRNAs has also been described. 9 MiRNAs are likely to be predominantly fine tuners of gene expression, 10, 11 but there is some evidence that on reaching a critical threshold, they may highly repress protein production and in so doing act as 'switches'. 12 Each miRNA may fine tune the expression of hundreds or even thousands of proteins, 10, 13 and it is estimated that over 60% of mammalian mRNAs are conserved targets for miRNAs. 2 Additionally, each mRNA may be targeted by many miRNAs. 2 This system therefore potentially has enormous regulatory capacity, but also possesses a complexity that can make it difficult to untangle.
MiRNAs IN ADIPOSE TISSUE AND ADIPOGENESIS
Support for an integral role of miRNA in adipose tissue formation and function has come from the studies demonstrating that inhibition of Drosha and Dicer in human mesenchymal stem cells inhibited differentiation into adipocytes 14 and that inhibition of Drosha in 3T3-L1 cells inhibited adipogenesis. 15 Mice engineered to have loss of Dicer in post-differentiation adipocytes have severely depleted white adipose tissue with reduced lipogenesisand adipogenesis-associated transcripts and were also noted to have normal brown adipose tissue but with reduced expression of genes involved in thermoregulation. 16 It should be noted, however, that disrupting Drosha and Dicer is a nonspecific model, which will have a global impact on miRNA expression.
In vivo studies of miRNAs in drosophila have shown that animals with miR-14 deleted have increased levels of triacylglycerol and diacylglycerol, and increasing miR-14 had the opposite effect, 17 whereas miR-278 null drosophila have higher circulating insulin and glucose and are lean, 18 and drosophila with miR-8-knockout have smaller body size and defective insulin signalling in the fat compartment (the equivalent of adipose tissue and liver). 19 Although these studies lend support to the importance of miRNA within fat, miR-14 and miR-278 do not have human homologues and so these results cannot be directly translated to human obesity research.
METHODOLOGIES IN MiRNA RESEARCH
Several high-throughput studies have demonstrated the up-and downregulation of miRNAs in animals, including humans, in whole-adipose tissue in lean or obese subjects and in different depots, and during adipogenesis of pre-adipocytes and human adipose-derived stem cells (hASCs) (see Table 1 ). There is a scope for further studies examining changing expression of miRNAs in dynamic conditions that modulate adipose tissue formation and function, such as during weight loss or gain. Although existing studies have identified some interesting and important candidates for further research, there is some inconsistency between global profiling studies in terms of the miRNAs that are identified. This may be due to integral differences in the types of cells or tissues used (for example, murine or human cells, primary cells or cell lines), discrepancies in the populations sampled or the conditions under which cells are cultured, different miRNA array platforms used or the use of inappropriate house-keeping genes against which to normalise the data. 20 Murine cell lines, such as the 3T3-L1 cell line, are the predominant models used for many experiments. It should be noted, however, that miRNA expression patterns and actions in murine tissue cannot always be extrapolated to humans, and differences between murine and human, and between primary cell and cell line, miRNA expression have been observed. 21 Nonetheless, these studies have identified some interesting candidates around which further research has centred.
Generally, the aim of miRNA-profiling studies is to detect the mature miRNA, as this exerts translational repression and as levels of the primary miRNA do not always correspond linearly with the mature transcript. 22 Several methods are currently available to determine the presence and abundance of miRNAs, the four most commonly used technologies being: microarray, RNA-seq, Northern-blot and quantitative real-time PCR (QPCR). MiRNA microarrays are available from a number of commercial sources and allow for the expression profiling of large numbers of miRNAs in parallel. They are, however, limited by the probes that are available for any given technology and caution should be used when relatively quantifying the different miRNAs present, as the binding affinity of each miRNA to its probe may vary. RNA-seq takes advantage of recent advances in high-throughput sequencing technologies. 23, 24 It allows the sequencing and direct quantification of all the small RNA molecules, independent of any a priori information, and so adds the potential for the identification of novel sequences, plus is able to resolve different members of miRNA families with only single-nucleotide differences. However, it has been suggested that the method of library preparation used may bias against the detection of some small RNA molecules 22 and so this technique is probably best used for relative quantification of miRNAs between samples rather than for absolute quantification. It is also prohibitively expensive for many and the large quantities of data generated require challenging bioinformatics analysis. Both RNA-seq and microarrays can be useful for demonstrating differential miRNA expression between different states, for example, lean and obese. They can also be used to create a picture of miRNA and mRNA associations and interactions within a tissue by combining the data from these bioinformatically. 25 Once a global profiling study has been undertaken, it is generally considered advisable to confirm results using a miRNAspecific method. The two most commonly used methods for this are Northern-blot analysis and QPCR. Northern-blot is considered the gold standard by many. It has the advantage of simultaneously displaying both the sizes and amounts of multiple small RNAs. However, it is very time consuming, many protocols use radioisotope probes and formaldehyde, and it lacks sensitivity. 26 More recent methodologies have addressed some of these issues, 26 however, the large amounts of RNA required for this method means that it is quite often not practical when using small clinical or cell samples. With these limitations in mind, QPCR is becoming increasingly popular. QPCR is sensitive, can be run on very small amounts of material and is quick. Considerations needed when undertaking QPCR quantitation of miRNA include the cDNA synthesis method, the chemistry used to detect the specific miRNA, the primer design and the selection of appropriate endogenous control transcripts to which to normalise your data. 20 Readers interested in QPCR methodology and the advantages and disadvantages of the different technologies available are directed toward reviews on this subject. 27, 28 Noninvasive techniques have now become available for visualising miRNA activity in living subjects and cells, offering further insights into the dynamics of miRNA function. 29 MiRNA imaging systems consisting of complementary sequences against the miRNA of interest attached to fluorescent protein tags can be used to track miRNA production and localisation within living cells, 30 and luciferase reporter-based systems have been used for in vivo imaging of miRNAs in animals. 31 This presents the possibility of using these techniques to visualise miRNAs in adipose tissue in different conditions, for instance during weight gain or loss, or during adipogenesis or pre-adipocyte proliferation.
MiRNA expression can be influenced by several factors. For example, one study used genome-wide genotyping to identify miRNA expression quantitative trait loci and found that genetic variants drive the expression of some miRNAs, 25 whereas the expression of many others is influenced by environmental factors. 32, 33 RNA-binding proteins have also been shown to affect miRNA processing and therefore expression, 34 and in so doing to influence biological processes. 35 Further research is required to clarify the relevance of RNA-binding proteins to miRNA regulation in obesity.
Without functional characterisation, it is difficult to know whether the observation that a miRNA is up-or downregulated implies that the miRNA is having an integral role, or whether it is a biomarker and its expression has been modulated by another coincidental factor. In order to establish the functional relevance of a miRNA and establish causality, one can examine miRNA expression changes over time in in vivo animal models of disease or examine the phenotypic changes that occur with gain or loss of the miRNA, either in vitro or in vivo.
Determining the targets of miRNAs is also important for understanding their function. Pairing between the miRNA and its target requires interaction by as few as six nucleotides of the seed sequence and is often not fully complimentary 13 and so determination of miRNA targets is a challenge. Bioinformatic approaches are useful for predicting putative targets. The outputs of some online miRNA target-prediction algorithms have been compared with experimental data and the sensitivities of various online prediction algorithms are estimated at between around 6 and 50%, with precision estimates ranging between around 25 and 50%. 36, 37 The outputs from different algorithms tend to be inconsistent and the question as to which target-prediction algorithms, or combinations of algorithms, are best remains controversial. The available tools and the approaches they use to predict miRNA-target interactions is well reviewed elsewhere. 38 It is therefore generally accepted that in silico predictions should be backed up by experimental approaches. Because of the small effects that a miRNA may have on the expression of many mRNAs, it is more straightforward to demonstrate miRNA target effects in vitro than to demonstrate differences in target networks between different conditions in vivo. The most commonly used approach is cloning of a 3 0 untranslated region mRNA target into a luciferase reporter, which is co-transfected into cells along with a miRNA mimic or inhibitor. This allows for validation of individual targets. Other approaches allow for experimental prediction of a range of targets of a miRNA. These include proteome analysis or transcriptome analysis (as miRNAs decrease the levels of many of their mRNA targets 39 ) after introduction or deletion of the miRNA of interest. More recently developed approaches, such as HITS-CLIP (high-throughput sequencing of RNAs isolated by cross-linking immunoprecipitation), 40 involve using an antibody to precipitate members of the Argonaute family along with the miRNA and its mRNA targets. These can then be sequenced and the bioinformatics can be used to create genome-wide miRNAmRNA interaction maps. This technique can be used to identify altered miRNA-mRNA networks in health and disease states. To date, these broader genome-wide approaches for target determination have not been applied to obesity research and the majority of investigators have validated only a few of the targets in the pathways of interest for a given miRNA.
Several studies have attempted to functionally characterise miRNAs within adipose tissue and to determine their targets. It should be noted that much of this functional work has used rodent cells as a model and that not all the miRNAs studied have been demonstrated to be regulated in human adipose tissue (see Table 1 ). Therefore, the extent to which some targets are relevant to human fat dysfunction remains to be elucidated. 41 Interestingly, many miRNAs that are upregulated in obesity are also found to be downregulated during adipogenesis, and vice versa, 33, 42 and there is evidence of impaired adipocyte differentiation in obesity. 43, 44 Several miRNAs have been shown to regulate commitment to an adipogenic lineage in multipotent stem cells or to enhance or regulate adipogenesis, and so miRNAs may contribute to governing adipocyte number and size. There is also evidence that adipocyte hypertrophy contributes to insulin resistance by encouraging macrophage infiltration and the release of inflammatory cytokines and increased ER stress, 45 and so by regulating adipocyte size, miRNAs may regulate the metabolic consequences of obesity as well as fat mass. In addition, miRNAs have also been shown to directly regulate adipose tissue metabolism.
MiRNAs THAT ENHANCE ADIPOGENESIS MiR-143 has been shown to increase during human and murine pre-adipocyte differentiation 33, [46] [47] [48] and inhibition of miR-143 inhibited differentiation in cultured human preadipocytes, 47 whereas ectopic overexpression by transfection enhanced triglyceride accumulation in differentiating 3T3-L1 pre-adipocytes. 33 MiR-143 is downregulated in adipose tissue samples from obese humans 21 and is downregulated in epididymal adipose tissue from ob/ob mice compared with wildtype mice, 33 but in another study was found to be upregulated in mesenteric adipose tissue and associated with weight gain in high-fat diet-induced obese mice, 49 a discrepancy that may have been caused by the different fat depots sampled or the different models of obesity used.
MiR-103 is upregulated during differentiation in 3T3-L1 cells 33, 46 and downregulated in obese mice, 33 and ectopic expression of miR-103 has been reported to enhance triglyceride accumulation in murine 3T3-L1 pre-adipocytes in differentiation. 33 It is also upregulated in porcine adipogenesis and inhibition of miR-103 inhibits adipogenesis. 50 In vivo, silencing of miR-103/107 in ob/ob and diet-induced obese C57BL/6J mice lead to improved insulin sensitivity via its action on Caveolin-1, a regulator of the insulin receptor, with the predominant effect being in adipose tissue. The mice were also found to have an increased number of small adipocytes after miR-103 silencing. 51 However, miR-103 does not change significantly during adipogenesis of a human cell line 42 and indeed has also been observed to be one of the most stably expressed miRNAs in human adipose tissue across a range of panels including in obesity, 20 and so the relevance of these findings to human adipogenesis and insulin resistance remains unclear.
The miR-30 family has been found to be important for adipogenesis. MiRs 30a-e were strongly upregulated during adipogenesis of human cells and inhibition of the miR-30 family inhibited adipogenesis. Overexpression of miR-30a and d stimulated adipogenesis, and it has been demonstrated that miR-30a and d target RUNX2, 52 an osteogenesis regulator that promotes adipogenesis when downregulated. 53 MiR-30c has independently been shown to be upregulated in adipogenesis and to enhance adipogenesis in hASCs, and appears to target two genes (PAI-1 and ALK2) in distinct pathways. Co-silencing both targets mimicked the pro-adipogenic effect of miR-30c, adding further weight to a biologically important role for miR-30. 54 MiR-204 expression increases during adipogenesis of mesenchymal stem cell lines. MiR-204 overexpression favours adipogenesis, whereas its inhibition favours osteogenesis, and miR-204 has also been shown to directly target RUNX2.
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The miR-17-92 cluster, which comprises miR-17-5p, miR-17-3p, miR-18, miR-19a, miR-20, miR-19b and miR-92-1, has been associated with cell proliferation in other tissues and cancers. 56 It is upregulated at the clonal expansion stage of adipogenesis and ectopic expression enhances adipogenesis and lipid accumulation. 15 MiR-17-92 was demonstrated to target Rb2/ p130, which is an important regulator of pre-adipocyte clonal expansion early in the differentiation process. 57 Another pro-adipogenic miRNA is miR-21, which has been shown to enhance adipogenesis of hASCs 58 while inhibiting cellular proliferation 59 and to target TGFBR2 58 and STAT3. 59 MiR-21 is upregulated in human obesity. 21 Similarly, miR-15a increases with increasing 3T3-L1 cell density, and overexpressing miR-15a represses cell numbers but increases cell size of murine adipocytes. 60 Another study demonstrated that miR-519d is overexpressed in human obesity, whereas peroxisome proliferator-activated receptor-alpha protein is repressed, and that proliferator-activated receptor-alpha is a direct target of miR519d. Proliferator-activated receptor-alpha in adipose tissue has been suggested to improve insulin sensitivity, inhibit adipocyte hypertrophy and reduce inflammation. 61 MiR-519d was ectopically overexpressed in a human cell line leading to enhanced lipid storage during adipogenesis, although this effect of miR519d was not linked with its actions on proliferator-activated receptor-alpha. 62 MiR-375 has been shown to enhance adipogenesis in 3T3-L1 cells, with inhibition of miR-375 having the converse effect. Ectopic overexpression of miR-375 also led to suppression of phosphorylation of ERK1/2, although no mechanism was demonstrated for this. 63 The role of the ERK pathway in adipogenesis is complex, with activation of ERK during the initial proliferative step and then its inhibition during later adipogenesis. 64 
MiRNAs THAT INHIBIT ADIPOGENESIS
The miR-27 family of miRNAs have been implicated as negative regulators of adipogenesis. MiR-27 is found to be downregulated during adipogenesis of 3T3-L1 cells 65, 66 and hASCs. 67 MiR-27 is increased in adipose tissue of obese mice compared with lean controls, 65 but has also been shown to be downregulated in the mature adipocyte fraction of adipose tissue in obese as opposed to lean mice. 66 MiR-27a has been shown to target peroxisome proliferator-activated receptor-gamma (PPARG) mRNA, 66, 67 and ectopic expression in 3T3-L1 cells 65, 66 and hASCs 67 reduced adipogenesis. In addition to targeting PPARG mRNA, miR-27 has been shown to target Wnt signalling during osteoblast formation, although this has not been confirmed during adipogenesis. 68 Its expression has been shown to be induced by hypoxia, 65 which is increased in obesity and thought of as a possible cause of adipose tissue dysfunction in obesity. 69 Another miRNA, miR-130 also inhibits adipogenesis by targeting PPARG mRNA, and it has been observed that adipose tissue from obese women had higher expression of miR-130 with lower expression of PPARG mRNA than non-obese women. 70 Let-7 is reported to inhibit clonal expansion and terminal differentiation of 3T3-L1 pre-adipocytes via suppression of HMGA2 mRNA and protein expression, 46 a high mobility group protein. Interestingly, mice with disruption of HMGA2 resist diet-induced obesity due to a reduced number of adipocytes, implicating it in proliferative expansion of pre-adipocytes. 71 Lin-28 is a binding protein that binds to let-7. Mice engineered to overexpress Lin-28 remained lean and glucose tolerant even on a high-fat diet. 72 Other miRNAs that have been characterised as inhibiting adipocyte differentiation include miR-138, which inhibits adipogenesis in hASCs, 73 and miR-448, which inhibits adipogenesis in 3T3-L1 cells by targeting kruppel-like factor 5. 74 
LIPID METABOLISM
Several miRNAs have been demonstrated to have a key role in lipid metabolism. For example, miR-122 has been shown to regulate cholesterol and fatty-acid oxidation in vivo in mice 75 and non-human primates, 76 mainly via hepatic actions. MiR-33 also contributes to the regulation of cholesterol metabolism, fatty-acid metabolism and insulin signalling in hepatocytes 77 and macrophages, 78 and in a recent study, treatment of non-human primates with anti-miR-33 oligonucleotide decreased very-lowdensity lipoprotein-associated triglycerides and increased highdensity lipoprotein. 79 MiR-378 is upregulated in adipogenesis of hASCs, 52 and miR-378/378* overexpression in the ST2 cell line increased lipid accumulation through increased de novo lipogenesis, without affecting adipogenesis. 80 Interestingly, there is a growing awareness that disease phenotypes can be caused not only just by changes in miRNA levels but also by polymorphisms that affect miRNA target action. For example, an association has been observed between SNPs in PLIN4 (a member of the perilipin family, that is expressed mainly in adipose tissue) and obesity and lipid phenotypes in humans. 81, 82 One of these SNPs was found to create a new binding site for miR-522, raising the possibility that variation in the PLIN4 locus acts partly via miRNA action. 82 
INSULIN RESISTANCE AND DIABETES
Genome-wide association studies that have attempted to uncover genes involved in the pathophysiology of diabetes have identified many SNPs in non-coding areas, implicating non-coding RNAs such as miRNAs in the pathogenesis of diabetes and dyslipidaemia. 83 Several studies have examined miRNA changes in diabetes, or have looked at miRNAs in specific tissues, and a number of these have investigated miRNAs within adipose tissue and their relationship to insulin resistance and diabetes.
Several miRNAs have been shown to be differentially regulated in adipose tissue in diabetes. MiR-222 and miR-27a were upregulated in hyperglycaemic rat models and were also upregulated by incubation of 3T3-L1 cells with high concentrations of glucose. 84 As discussed above, miR-27 is also implicated as a negative regulator of adipogenesis 65, 66 and has altered expression in murine obesity. 65 Additionally, miR-29 is upregulated in adipose tissue in mouse models of diabetes 85, 86 and is exposed to increased concentrations of glucose in 3T3-L1 cells. 84, 85 Furthermore, transfection of miR-29 into 3T3-L1 cells led to increased insulin resistance. 85 MiR-125a was shown by RT-PCR to be overexpressed in liver in rat models of type 2 diabetes, and suggested by microarray data to also be nonsignificantly overexpressed in adipose tissue. The authors compared mRNA arrays with in silico-predicted targets of miR-125a and found enrichment for downregulated mRNAs of putative miR-125a targets as predicted by one algorithm, which was weaker in liver than in adipose. However, they also found an enrichment for putative miR-125a targets that were upregulated at the mRNA level and did not find any enrichment with the other two algorithms tested. 86 In vitro, miR-320 increases 50-fold in 3T3-L1 cells rendered insulin resistance by incubation with glucose and insulin, and miR-320 transfection improved insulin sensitivity of insulin-resistant 3T3-L1 cells. 32 As discussed above, miR-103 and 107 may also have a role as a negative regulator of insulin sensitivity. 51 The contribution of miRNAs to diabetes pathophysiology in tissues other than adipose tissue is reviewed elsewhere. 87, 88 INFLAMMATION In addition to acting as an energy-storage depot, there is an increasing evidence that adipose tissue is an active metabolic and endocrine organ and that in obesity, adipose tissue becomes infiltrated with macrophages 89 and produces pro-inflammatory and pro-atherogenic adipokines. 45 The inflammatory environment within adipose tissue in obesity has been linked with insulin resistance and an increased risk of complications such as atherosclerosis. 45, 90 MiRNAs have been demonstrated to have an important role in regulating inflammation. 91 Indeed, some human inflammatory autoimmune diseases are associated with autoantibodies to the argonaute protein, 92 making it tempting to speculate that miRNA dysregulation and inflammation are closely entwined.
It has been observed that many miRNAs that change in obesity in mice are also differentially regulated by creating an inflammatory environment in vitro by incubating 3T3-L1 cells with TNFa. 33 Given the importance of inflammation to adipose tissue dysfunction, the role of miRNAs in adipose tissue inflammation is an area that warrants further research.
BROWN ADIPOSE TISSUE
Adipose tissue is composed of two distinct subsets of adipocyte; brown and white. Brown adipose tissue is concerned with thermoregulation and energy expenditure as opposed to energy storage 93 and represents an attractive therapeutic target for weight loss following its identification in adult humans. 94 Brown adipocytes have been found to have a gene expression pattern, and therefore potentially lineage, which is more similar to muscle than to white adipocytes. 95 MiRNAs are differently expressed in brown and white adipocytes, with brown adipocyte sharing a developmental signature similar to muscle. 96 For example, miR-143, which is highly expressed in white adipose tissue and has a role in adipogenesis, has low expression in brown adipocytes, whereas three miRNAs associated with muscle, 97 miR-1, miR-206 and miR-133a, were absent from white adipocytes but highly expressed in brown pre-adipocytes and brown adipocytes. It remains to be seen whether this signature is crucial to function or whether manipulation of miRNAs can alter the cellular phenotype. The miR-193b-365 cluster has been demonstrated to be enriched in brown fat and is a regulator of brown adipocyte differentiation, in that knocking down miR-193b-365 expression in brown pre-adipocytes impaired adipogenesis and encouraged myogenesis, and forced expression induced myoblasts to differentiate into brown adipocytes. 98 
THE ROLE OF MiRNAs IN PARACRINE AND ENDOCRINE COMMUNICATION
In addition to their regulation of intracellular signalling, there is a growing evidence that miRNAs are involved in signalling between cells in the same tissue and between separate tissues within the body. Microvesicles are secreted by many different cell types 99 and are now recognised to be also secreted by adipocytes. These allow the passage of cytokines, mRNAs and miRNAs that may then be taken up elsewhere in the body and be functional in the recipient cell. 100 One study found that adipose-derived microvesicles isolated from 3T3-L1 cells contain similar RNAs and miRNAs to the host cell. These microvesicles mediated transport of miRNAs into macrophages, and microvesicles containing adipose-specific transcripts were also isolated from rat serum. 101 Macrophages containing microvesicles have also been shown to be able to transfer miRNA to remote tissues in vivo. 102 Additionally, miRNAs have been demonstrated to be transported in vivo in association with high-density lipoprotein. The expression of these miRNAs differs with disease states, and high-density lipoprotein is able to transfer miRNAs to recipient cells, where they lead to altered gene expression. 103 These findings suggest a novel role for high-density lipoprotein in the intercellular transport of miRNAs.
Continuing research into this area will lead to an enhanced understanding of the role microvesicles have in paracrine and endocrine communication and provide valuable information to help us target miRNAs to tissues therapeutically.
MiRNA AS BIOMARKERS
Recently, miRNAs have attracted attention as potential biomarkers of disease and there is a growing interest in using peripheral blood sampling to investigate miRNA profiles of remote tissues. 104 The possibility of using miRNA signatures to aid diagnosis or tailor treatment is exciting, but to date there are limited studies investigating miRNA as biomarkers of obesity or adipose tissue function. In one recent paper, miRNAs were extracted from paired omental and subcutaneous adipose tissue and peripheral blood from 50 obese and non-obese subjects. MiR-17-5p and miR-132 differed between obese and non-obese omental fat, a change that was reflected in peripheral blood, suggesting a potential role for miRNAs as biomarkers of adipose tissue. 105 
THERAPEUTIC USE OF MiRNAs
In 2005, it became possible to manipulate miRNAs in vivo by the injection of 'antagomirs' into the peripheral blood. 106 More recently, locked nucleic acids have been shown to be capable of potently antagonising miRNAs in vivo. 76 Clinical trials of miRNA manipulation in humans are now underway. 107 There are a number of potential problems with miRNAs in therapeutics. Challenges remain with manipulating miRNA in vivo specifically within a target tissue, such as adipose tissue. Given the large number of targets of miRNAs, there is a considerable risk of off-target effects. Additionally, there is a risk of saturation of the processing or degradation pathways and knock-on effects to other miRNAs, and in one study in mice this was fatal. 108 However, the potential of miRNAs to modulate the metabolic pathways holds promise.
SUMMARY
MiRNAs represent an elegant network of regulation, both fine tuning and dramatically altering the expression of genes involved in adipose tissue formation and function. MiRNA profiling has revealed changing miRNA expression in adipose tissue and functional studies have attributed roles to some of these miRNAs within adipogenesis, insulin resistance and inflammation. MiRNAs look likely to be involved in communication between cells and tissues and are increasingly attractive as therapeutic targets. Given the speed with which miRNA research has evolved and changed our understanding of cellular physiology, the future of miRNA research promises to be exciting.
